Eeyarestatin 24 impairs SecYEG-dependent protein trafficking and inhibits growth of clinically relevant pathogens

Maurice Steenhuis, Gregory M. Koningstein, Julia Oswald, Tillman Pick, Sarah O'Keefe, Hans Georg Koch, Adolfo Cavalié, Roger C. Whitehead, Eileithyia Swanton, Stephen High, Joen Luirink

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Eeyarestatin 1 (ES1) is an inhibitor of endoplasmic reticulum (ER) associated protein degradation, Sec61-dependent Ca2+ homeostasis and protein translocation into the ER. Recently, evidence was presented showing that a smaller analog of ES1, ES24, targets the Sec61-translocon, and captures it in an open conformation that is translocation-incompetent. We now show that ES24 impairs protein secretion and membrane protein insertion in Escherichia coli via the homologous SecYEG-translocon. Transcriptomic analysis suggested that ES24 has a complex mode of action, probably involving multiple targets. Interestingly, ES24 shows antibacterial activity toward clinically relevant strains. Furthermore, the antibacterial activity of ES24 is equivalent to or better than that of nitrofurantoin, a known antibiotic that, although structurally similar to ES24, does not interfere with SecYEG-dependent protein trafficking. Like nitrofurantoin, we find that ES24 requires activation by the NfsA and NfsB nitroreductases, suggesting that the formation of highly reactive nitroso intermediates is essential for target inactivation in vivo.

Original languageEnglish
JournalMolecular Microbiology
Volume115
Issue number1
Pages (from-to)28-40
Number of pages13
ISSN0950-382X
DOIs
Publication statusPublished - 15 Aug 2020
Externally publishedYes
MoE publication typeA1 Journal article-refereed

Bibliographical note

Funding Information:
This study was supported by the NWO graduate program (022.005.031) awarded to MS, the German Science Foundation (grant SPP2002/KO2184/9‐1, grant KO2184/8) and Project‐ID 403222702/SFB 1381 awarded to HGK and by a Wellcome Trust Investigator Award in Science (204957/Z/16/Z) awarded to SH.

Funding Information:
This study was supported by the NWO graduate program (022.005.031) awarded to MS, the German Science Foundation (grant SPP2002/KO2184/9-1, grant KO2184/8) and Project-ID 403222702/SFB 1381 awarded to HGK and by a Wellcome Trust Investigator Award in Science (204957/Z/16/Z) awarded to SH. We thank Karin van Dijk (Amsterdam UMC, VU University), Juan L. Ramos (Estaci?n Experimental del Zaidin) and Dan I. Andersson (Uppsala University) for kindly providing E. coli strains resistant to nitrofurantoin. We also thank Helen I. Zgurskaya (University of Oklahoma) for providing the E. coli FhuA ?C/?4L strain. In addition, we thank Peter van Ulsen for critically reading the manuscript and for valuable input in the project.

Publisher Copyright:
© 2020 The Authors. Molecular Microbiology published by John Wiley & Sons Ltd

Fields of Science

  • eeyarestatin 1
  • Escherichia coli
  • nitrofurantoin
  • Sec61

Cite this